Zhu, Hongcheng
Liu, Qiufang
Xu, Hao
Mo, Miao
Wang, Zezhou
Lu, Kui
Zhou, Jialiang
Chen, Junqiang
Zheng, Xiangpeng
Ye, Jinjun
Ge, Xiaolin
Luo, Honglei
Liu, Qi
Deng, Jiaying
Ai, Dashan
Hao, Shengnan
Zhang, Junhua
Tseng, I Hsuan
Song, Shaoli
Chen, Yun
Zhao, Kuaile
Clinical trials referenced in this document:
Documents that mention this clinical trial
Dose escalation based on 18F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)
https://doi.org/10.1186/s13014-022-02099-y
Funding for this research was provided by:
Chinese Society of Clinical Oncology (Y-Young2020-0003)
Beijing Bethune Charitable Foundation (flzh202119)
National Natural Science Foundation of China (82102827, 81872454)
Article History
Received: 12 March 2022
Accepted: 7 July 2022
First Online: 29 July 2022
Declarations
:
: The final protocol was approved by the Ethics Committee of Fudan University Shanghai Cancer Center (1808190–10).
: Not applicable.
: The authors declare that they have no financial or non-financial competing interests.